Benzinga | Feb 4, 2021 11:04AM EST

Dynavax, Serum Institute Start Phase 1 Trial For Tdap Booster Vaccine

* Dynavax Technologies Corporation (NASDAQ: DVAX) and Serum Institute of India (SII) have dosed the first patient in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate, adjuvanted with CpG 1018.

* The Phase 1 trial will evaluate the adjuvanted vaccine candidate's safety, tolerability, and immunogenicity in healthy volunteers 10 to 22 years of age.

* Dynavax expects Phase 1 study results in the fourth quarter of 2021.

* Under the collaboration, Dynavax has exclusive worldwide rights to commercialize the vaccine, except that the Serum Institute of India has exclusive rights to distribute in India and fulfill WHO/UNICEF tender contracts. The parties are responsible for clinical development costs in their respective territories.

* Price Action: DVAX shares down 0.96% at $9.32 on the last check Thursday.